Literature DB >> 28438688

Hepatitis B virus reactivation during hepatitis C direct-acting antiviral therapy in patients with previous HBV infection.

Naoki Kawagishi1, Goki Suda2, Masahiro Onozawa3, Megumi Kimura1, Osamu Maehara1, Jun Ito1, Masato Nakai1, Takuya Sho1, Mitsuteru Natsuizaka1, Kenichi Morikawa1, Koji Ogawa1, Naoya Sakamoto4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28438688     DOI： 10.1016/j.jhep.2017.04.008

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  6 in total

Review 1.  Hepatitis B virus (HBV) reactivation-The potential role of direct-acting agents for hepatitis C virus (HCV).

Authors:  Jason T Blackard; Kenneth E Sherman
Journal:  Rev Med Virol       Date:  2018-05-15       Impact factor: 6.989

2.  Serum IL-1β predicts de novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapy.

Authors:  Naoki Kawagishi; Goki Suda; Ryotaro Sakamori; Takeshi Matsui; Masahiro Onozawa; Zijian Yang; Sonoe Yoshida; Masatsugu Ohara; Megumi Kimura; Akinori Kubo; Osamu Maehara; Qingjie Fu; Shunichi Hosoda; Yoshimasa Tokuchi; Kazuharu Suzuki; Masato Nakai; Takuya Sho; Kenichi Morikawa; Mitsuteru Natsuizaka; Koji Ogawa; Hajime Sakai; Shunsuke Ohnishi; Masaru Baba; Tetsuo Takehara; Naoya Sakamoto
Journal:  Sci Rep       Date:  2022-10-07       Impact factor: 4.996

3.  Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection.

Authors:  Kazuharu Suzuki; Goki Suda; Yoshiya Yamamoto; Ken Furuya; Masaru Baba; Akinobu Nakamura; Hideaki Miyoshi; Megumi Kimura; Osamu Maehara; Ren Yamada; Takashi Kitagataya; Koji Yamamoto; Taku Shigesawa; Akihisa Nakamura; Masatsugu Ohara; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Shunsuke Ohnishi; Naoya Sakamoto
Journal:  J Gastroenterol       Date:  2020-11-19       Impact factor: 7.527

4.  Absence of HBV Reactivation in Patients With Resolved HBV Infection Following DAA Therapy for Hepatitis C: A 1-Year Follow-up Study.

Authors:  Marcus M Mücke; Victoria T Mücke; Kai-Henrik Peiffer; Christoph Sarrazin; Stefan Zeuzem; Annemarie Berger; Johannes Vermehren
Journal:  Open Forum Infect Dis       Date:  2018-12-15       Impact factor: 3.835

5.  Hepatitis C virus infection suppresses hepatitis B virus replication via the RIG-I-like helicase pathway.

Authors:  Kazuhiro Murai; Hayato Hikita; Yugo Kai; Yasuteru Kondo; Makoto Fukuoka; Keisuke Fukutomi; Akira Doi; Takuo Yamai; Tasuku Nakabori; Ryo Fukuda; Takeshi Takahashi; Kei Miyakawa; Hiroshi Suemizu; Akihide Ryo; Ryoko Yamada; Takahiro Kodama; Ryotaro Sakamori; Tomohide Tatsumi; Tetsuo Takehara
Journal:  Sci Rep       Date:  2020-01-22       Impact factor: 4.379

6.  Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B.

Authors:  Kazuharu Suzuki; Goki Suda; Yoshiya Yamamoto; Satoshi Abiko; Kenji Kinoshita; Shuichi Miyamoto; Ryo Sugiura; Megumi Kimura; Osamu Maehara; Ren Yamada; Takashi Kitagataya; Taku Shigesawa; Masatsugu Ohara; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Naoya Sakamoto
Journal:  PLoS One       Date:  2022-01-20       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.